Capricor Therapeutics aligned with the FDA on key aspects of the HOPE-3 trial design for CAP-1002, a cell therapy for Duchenne muscular dystrophy (DMD).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.